Get involved: send your photos, videos, news & views by texting OXFORD NEWS to 80360 or email us
Firm starts phase three of cat allergy trials
1:00pm Thursday 25th October 2012 in News
Biotech firm Circassia based at the Oxford Science Park, has started phase three trials of cat allergy treatment.
The new study follows encouraging results in previous trials for the ToleroMune vaccine.
Chief executive Steve Harris said: “Tens of millions of people are allergic to cats in the US and Europe, and the disease can have a major effect on patients’ quality of life.”